Relapsing Multiple Sclerosis (RMS) - Epidemiology Forecast to 2032

January 2022 | 60 pages | ID: R21B52A47C4EN
DelveInsight

Abstracts

This report can be delivered to the clients within 5-7 Business Days

DelveInsight's 'Relapsing Multiple Sclerosis (RMS) - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Relapsing Multiple Sclerosis (RMS) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032

Relapsing Multiple Sclerosis (RMS) Understanding

The DelveInsight Relapsing Multiple Sclerosis (RMS) epidemiology report gives a thorough understanding of the Relapsing Multiple Sclerosis (RMS) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Relapsing Multiple Sclerosis (RMS) in the US, Europe, and Japan. The report covers the detailed information of the Relapsing Multiple Sclerosis (RMS) epidemiology scenario in seven major countries (US, EU5, and Japan).

Relapsing Multiple Sclerosis (RMS) Epidemiology Perspective by DelveInsight

The Relapsing Multiple Sclerosis (RMS) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Relapsing Multiple Sclerosis (RMS) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Relapsing Multiple Sclerosis (RMS) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Relapsing Multiple Sclerosis (RMS) Detailed Epidemiology Segmentation

The Relapsing Multiple Sclerosis (RMS) epidemiology covered in the report provides historical as well as forecasted Relapsing Multiple Sclerosis (RMS) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The DelveInsight Relapsing Multiple Sclerosis (RMS) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

• The Relapsing Multiple Sclerosis (RMS) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Relapsing Multiple Sclerosis (RMS) Epidemiology Report and Model provide an overview of the global trends of Relapsing Multiple Sclerosis (RMS) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight into the historical and forecasted patient pool of Relapsing Multiple Sclerosis (RMS) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps recognize the growth opportunities in the 7MM for the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Relapsing Multiple Sclerosis (RMS)
• The report provides the segmentation of the Relapsing Multiple Sclerosis (RMS) epidemiology

Report Highlights

• 11-year Forecast of Relapsing Multiple Sclerosis (RMS) epidemiology
• 7MM Coverage
• Prevalent and Diagnosed Cases of Relapsing Multiple Sclerosis (RMS)
• Cases of Relapsing Multiple Sclerosis (RMS) by Mutation Types
• Relapsing Multiple Sclerosis (RMS) Cases associated with Clinical Manifestations

KOL views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Relapsing Multiple Sclerosis (RMS)?
• What are the key findings pertaining to the Relapsing Multiple Sclerosis (RMS) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?
• What would be the total number of patients of Relapsing Multiple Sclerosis (RMS) across the 7MM during the forecast period (2019-2032)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
• What is the disease risk, burden and unmet needs of Relapsing Multiple Sclerosis (RMS)?
• What are the currently available treatments of Relapsing Multiple Sclerosis (RMS)?

Reasons to buy

The Relapsing Multiple Sclerosis (RMS) Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global Relapsing Multiple Sclerosis (RMS) market
• Quantify patient populations in the global Relapsing Multiple Sclerosis (RMS) market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Relapsing Multiple Sclerosis (RMS) therapeutics in each of the markets covered
• Understand the magnitude of Relapsing Multiple Sclerosis (RMS) population by its epidemiology
• The Relapsing Multiple Sclerosis (RMS) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Contents

1. KEY INSIGHTS

2. EXECUTIVE SUMMARY OF RELAPSING MULTIPLE SCLEROSIS (RMS)

3. RELAPSING MULTIPLE SCLEROSIS (RMS): DISEASE BACKGROUND AND OVERVIEW

3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis

4. PATIENT JOURNEY

5. EPIDEMIOLOGY AND PATIENT POPULATION

5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
  5.3.1. Relapsing Multiple Sclerosis (RMS) Epidemiology Scenario in the 7MM (2019- 2032)
5.4. United States Epidemiology
  5.4.1. Relapsing Multiple Sclerosis (RMS) Epidemiology Scenario in the United States (2019- 2032)
5.5. EU-5 Country-wise Epidemiology
  5.5.1. Germany Epidemiology
    5.5.1.1. Relapsing Multiple Sclerosis (RMS) Epidemiology Scenario in Germany (2019- 2032)
  5.5.2. France Epidemiology
    5.5.2.1. Relapsing Multiple Sclerosis (RMS) Epidemiology Scenario in France (2019- 2032)
  5.5.3. Italy Epidemiology
    5.5.3.1. Relapsing Multiple Sclerosis (RMS) Epidemiology Scenario in Italy (2019- 2032)
  5.5.4. Spain Epidemiology
    5.5.4.1. Relapsing Multiple Sclerosis (RMS) Epidemiology Scenario in Spain (2019- 2032)
  5.5.5. United Kingdom Epidemiology
    5.5.5.1. Relapsing Multiple Sclerosis (RMS) Epidemiology Scenario in the United Kingdom (2019-2032)
5.6. Japan Epidemiology
  5.6.1. Relapsing Multiple Sclerosis (RMS) Epidemiology Scenario in Japan (2019- 2032)

6. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES

6.1. Relapsing Multiple Sclerosis (RMS) Treatment and Management
6.2. Relapsing Multiple Sclerosis (RMS) Treatment Algorithm

7. KOL VIEWS

8. UNMET NEEDS

9. APPENDIX

9.1. Bibliography
9.2. Report Methodology

10. DELVEINSIGHT CAPABILITIES

11. DISCLAIMER

12. ABOUT DELVEINSIGHT

*The table of contents is not exhaustive; will be provided in the final report

List Of Tables

LIST OF TABLES

List of Table:
Table 1: Relapsing Multiple Sclerosis (RMS) Epidemiology in 7MM (2019-2032)
Table 2: Relapsing Multiple Sclerosis (RMS) Diagnosed and Treatable Cases in 7MM (2019-2032)
Table 3: Relapsing Multiple Sclerosis (RMS) Epidemiology in the United States (2019-2032)
Table 4: Relapsing Multiple Sclerosis (RMS) Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: Relapsing Multiple Sclerosis (RMS) Epidemiology in Germany (2019-2032)
Table 6: Relapsing Multiple Sclerosis (RMS) Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: Relapsing Multiple Sclerosis (RMS) Epidemiology in France (2019-2032)
Table 8: Relapsing Multiple Sclerosis (RMS) Diagnosed and Treatable Cases in France (2019-2032)
Table 9: Relapsing Multiple Sclerosis (RMS) Epidemiology in Italy (2019-2032)
Table 10: Relapsing Multiple Sclerosis (RMS) Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: Relapsing Multiple Sclerosis (RMS) Epidemiology in Spain (2019-2032)
Table 12: Relapsing Multiple Sclerosis (RMS) Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: Relapsing Multiple Sclerosis (RMS) Epidemiology in the United Kingdom (2019-2032)
Table 14: Relapsing Multiple Sclerosis (RMS) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Table 15: Relapsing Multiple Sclerosis (RMS) Epidemiology in Japan (2019-2032)
Table 16: Relapsing Multiple Sclerosis (RMS) Diagnosed and Treatable Cases in Japan (2019-2032)

List Of Figures

LIST OF FIGURES

List of Figures
Figure 1 Relapsing Multiple Sclerosis (RMS) Epidemiology in 7MM (2019-2032)
Figure 2 Relapsing Multiple Sclerosis (RMS) Diagnosed and Treatable Cases in 7MM (2019-2032)
Figure 3 Relapsing Multiple Sclerosis (RMS) Epidemiology in the United States (2019-2032)
Figure 4 Relapsing Multiple Sclerosis (RMS) Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5 Relapsing Multiple Sclerosis (RMS) Epidemiology in Germany (2019-2032)
Figure 6 Relapsing Multiple Sclerosis (RMS) Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7 Relapsing Multiple Sclerosis (RMS) Epidemiology in France (2019-2032)
Figure 8 Relapsing Multiple Sclerosis (RMS) Diagnosed and Treatable Cases in France (2019-2032)
Figure 9 Relapsing Multiple Sclerosis (RMS) Epidemiology in Italy (2019-2032)
Figure 10 Relapsing Multiple Sclerosis (RMS) Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11 Relapsing Multiple Sclerosis (RMS) Epidemiology in Spain (2019-2032)
Figure 12 Relapsing Multiple Sclerosis (RMS) Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13 Relapsing Multiple Sclerosis (RMS) Epidemiology in the United Kingdom (2019-2032)
Figure 14 Relapsing Multiple Sclerosis (RMS) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Figure 15 Relapsing Multiple Sclerosis (RMS) Epidemiology in Japan (2019-2032)
Figure 16 Relapsing Multiple Sclerosis (RMS) Diagnosed and Treatable Cases in Japan (2019-2032)
*The table of contents is not exhaustive; will be provided in the final report